Lithium technology has ushered in a new era of batteries with exceptionally high energy density for a reasonably low cost.

BMS is paying $62.50 per share in cash for San Diego-based RayzeBio and its pipeline of radiopharmaceuticals for solid tumours – including a late-stage candidate for neuroendocrine tumours (NETs ...

Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab – was unable to improve on Opdivo alone in the RELATIVITY-098 ...